TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Time to void
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: change of sedation depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Who Received IV-rtPA Treatment Within 3 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Patients Who Received IV-rtPA Treatment Within 4.5 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: motor dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: sensory dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in analgetic need
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Fecal Potassium Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficiency of rTMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful removal of CVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Disease Free Survival (3-y DFS)
Endpoint domain: Mortality/survival
Primary endpoint: Weekly mean of the 24h average pain scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Incidence of HIV-1 Seroconversion
Endpoint domain: Mortality/survival
Primary endpoint: Change in diameter of right internal jugular vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Prevalence of histopathological pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS (visual analogue pain scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frankel score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: mJOA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Improvement of hematologic tolerance to therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement of gastrointestinal tolerance to therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Referfusion ratio in patients with symptom onset within 12 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Door-to-balloon time in patients with symptom onset within 12 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: In-hospital morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of copies/ml plasma HIV - RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of inflammatory cells in nasal lavage samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cerebellar functions measured by SARA scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical Dementia Rating Scale- Frontotemporal dementia Sumo of Boxes (CDR-FTD-SOB)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percent Change in Serum Triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall summary score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incident pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: HIV transmission risks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Amount of sputum secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucus viscoelasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective feeling of ease to expectorate
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Saturation Pattern Detection (SPD) Indicative of Repetitive Reductions in Air Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants Requiring Airway Support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number Of Subjects Reporting Solicited Local and Systemic Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number Of Subjects Reporting Unsolicited Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number Of Subjects Reporting Unsolicited Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: tolerance of enteral feedings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Elevated Glut-1 gene and protein expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of units of ABPs administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Breath-by-breath oxygen consumption (VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a Maximum NRS Score of 1 or Less
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence Rate of Malignancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence Rate of Myocardial Infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence Rate of Viral Encephalitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quality and speed of wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of nasal polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: muscle recruitment patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: major amputation (above the ankle)
Endpoint domain: Mortality/survival
Primary endpoint: persisting critical limb ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Improvement of hemispatial neglect scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infection related to CIEDs
Endpoint domain: Adverse events/effects
Primary endpoint: Appropriate ICD Therapies effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oxygen desaturation below 92%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Central subfield macular thickness change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Investigator's Rating of Standardized Global Photographs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Participant Rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Medical Research Council sum score (MRC-SS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Status Score for the ICU (FSS-ICU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective assessment of satiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety of GLP-1 CellBeads®
Endpoint domain: Adverse events/effects
Primary endpoint: Safety through 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in MR acutely and at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functioning according to Functioning Assessment Short-Test
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Manometric improvement in IRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: arterial oxygenation differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinical outcomes associated with ERCC1 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating Concentrations of Reproductive Hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Circulating Concentrations of IGF Axis Proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: aMMP-8 test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Vancomycin Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Seroma Vancomycin Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RANKL levels in Gingival Crevicular Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Osteoprotegrin levels in Gingival Crevicular Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Physical Examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-Lead ECGs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical Laboratory Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in overactive bladder symptoms score (OABSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events associated with treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Hypoglycemic Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in PTSD Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of placental malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety of 99mTc-NM02 through Adverse Event Monitoring
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of a total home smoking ban
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Loco-regional disease free survival at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Brain wave activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pupilometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes from baseline PaO2 (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes from baseline ScvO2 (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overground walking capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants enrolled per month
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety of therapeutic agents
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of en-masse retraction of anterior teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score of severity of oral inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of first episode of acute urinary retention (AUR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: health care costs related to asthma
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Complete Response (CR or CRi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival without moderate or severe bronchopulmonary dysplasia (BPD)
Endpoint domain: Mortality/survival
Primary endpoint: Cystoscopic response at 6 months after initiation radiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall disease-specific survival
Endpoint domain: Mortality/survival
Primary endpoint: body composition analysis (Arm-, Trunk-, Leg Fat composition)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants performing MRI without sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of apixaban
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Verbal Score for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline VISA-P score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of preterm delivery
Endpoint domain: Mortality/survival
Primary endpoint: Stress-MRI evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to severe COVID-19 infection
Endpoint domain: Mortality/survival
Primary endpoint: Correlation of optical spectra measurements with biopsy tissue samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ribonucleic acid (RNA) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Alive at 72 Hours After Episode
Endpoint domain: Mortality/survival
Primary endpoint: Overall Morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interventricular mechanical delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Distribution of candidate genotypes and alleles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance of empty versus filled bladder radiotherapy treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in size of DCIS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety (local and systemic reactogenicity signs and symptoms)
Endpoint domain: Adverse events/effects
Primary endpoint: Confirmed tumor response (CR, PR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time in therapeutic INR range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pediatric Quality of Life Inventory Transplant Module (PedsQL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants with MACEs within 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: WHO functional classification
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Tumor-to-background ratio for detection of (pre)malignant lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with symptoms or changes in vital signs
Endpoint domain: Adverse events/effects
Primary endpoint: Wechsler Intelligence Scale for Children
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Plasma refilling rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: efavirenz AUC0-24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: efavirenz Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death or Recovery
Endpoint domain: Mortality/survival
Primary endpoint: Physical fitness including cardiovascular functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oxygen transport and utilization of exercising skeletal muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHDRS - IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tuberculin skin test positive rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: quantiferon positive rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent Change in Total Kidney Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: WOMAC VAS walking pain at week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Catheter-related Bladder Discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic control measured as HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood loss as estimated by postoperative decreases in haemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Drug-Drug Interaction (DDI) diagnosis
Endpoint domain: Adverse events/effects
Primary endpoint: area under the concentration-time curve from the time of dosing extrapolated to time infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the concentration-time curve from 0 to 72 hours (AUC72)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe acute GVHD (grades 3 and 4)
Endpoint domain: Adverse events/effects
Primary endpoint: Grade greater than or equal to 3 infusional toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Graft failure (failure to achieve ANC greater than or equal to 500/mm^3 of donor origin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of Treatment-Emergent Serious Adverse Events (SAEs) at Week 24
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment-Emergent Adverse Events (AEs) at Week 24
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with plasma HBV DNA < 20 IU/mL at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment entry and retention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient Rated Tennis Elbow Evaluation (PRTEE)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of patients achieving HbA1c level ≤ 7 %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Paclitaxel pharmacokinetics (PK) parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: precision-grip force error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genetic polymorphism frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI BOLD signal change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Patient Movement and MRI Interruption
Endpoint domain: Adverse events/effects
Primary endpoint: Case Times
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Treatment Effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores in TBI group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid consumption in milligrams
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain Score given as Numeric Rating Scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Failure of primary treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of POL6326
Endpoint domain: Adverse events/effects
Primary endpoint: Development of a near fatal asthma exacerbation
Endpoint domain: Adverse events/effects
Primary endpoint: Delayed Onset Muscle Soreness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in plasma insulin/glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in plasma lipids/lipoproteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of cat allergen inducing bronchial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in pruritus Visual Analogic Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of patients alive without mechanical ventilation and free of RRT at Day 28
Endpoint domain: Mortality/survival
Primary endpoint: Changes in the amount of immune cells in the peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in inflammatory cytokines in the peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in intracellular activation markers in T-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in intracellular activation markers in monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lumbar spine flexion changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expectation of pain changes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Expectation of harm changes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing